Friday, July 10, 2026

Patent intelligence · US

US 12285473

Cancer vaccines targeting MUC16 and uses thereof

granted A61KA61K2039/53A61K2039/54A61K2039/572
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 75
Patent details — US 12285473
Jurisdiction
US
Status
granted
Grant date
Apr 29, 2025
Expiration
Apr 24, 2045
Claims
16
CPC classes
A61K, A61K2039/53, A61K2039/54, A61K2039/572
View on Google Patents ↗

Quick answer

US 12285473 (Cancer vaccines targeting MUC16 and uses thereof) is held by Inovio Pharmaceuticals, Inc.. Status: granted. Granted Apr 29, 2025. Expires Apr 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
16
CPC classes
A61K, A61K2039/53, A61K2039/54, A61K2039/572, A61K39/00117, A61P

More from Inovio Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12280108

    Vaccines having an antigen and interleukin-21 as an adjuvant

    Inovio Pharmaceuticals, Inc. · Expires Apr 17, 2045

    granted
  2. US 12251561

    Minimally invasive dermal electroporation device

    Inovio Pharmaceuticals, Inc. · Expires Mar 13, 2045

    granted
  3. US 12240872

    Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

    Inovio Pharmaceuticals, Inc. · Expires Feb 27, 2045

    granted
  4. US 12161706

    Cancer vaccines targeting BORIS and uses thereof

    Inovio Pharmaceuticals, Inc. · Expires Dec 5, 2044

    granted
  5. US 12109258

    Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections

    Inovio Pharmaceuticals, Inc. · Expires Oct 3, 2044

    granted
  6. US 12064473

    Cancer vaccines targeting Survivin and uses thereof

    Inovio Pharmaceuticals, Inc. · Expires Aug 15, 2044

    granted
  7. US 12054537

    Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies

    Inovio Pharmaceuticals, Inc. · Expires Aug 1, 2044

    granted

Frequently asked questions

What is US patent 12285473?

US 12285473 (Cancer vaccines targeting MUC16 and uses thereof) is held by Inovio Pharmaceuticals, Inc.. Status: granted. Granted Apr 29, 2025. Expires Apr 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12285473?

Inovio Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 75 pharmaceutical patents for this assignee.

When does US 12285473 expire?

Our index shows an expiration date of Apr 24, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.